Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Effective treatment and management of Von Willebrand disease (VWD) requires a coordinated, patient‑centered approach that blends medical expertise with personalized care plans. VWD is the most common inherited bleeding disorder, affecting roughly 1 % of the global population, yet many patients remain undiagnosed until they experience significant bleeding events. This page provides a detailed guide for international patients seeking expert hematology services at Liv Hospital, outlining the full spectrum of therapeutic options, lifestyle adaptations, and the supportive infrastructure that ensures a seamless treatment journey.
Our comprehensive treatment and management strategy begins with an accurate diagnosis, followed by a tailored regimen that addresses the specific type and severity of VWD. Whether you are preparing for a routine dental procedure, planning major surgery, or simply looking to minimize daily bleeding risks, the information below will help you understand the options available and how Liv Hospital can facilitate a smooth, safe, and effective care experience.
Throughout this guide, you will find evidence‑based recommendations, practical tips, and a clear outline of the services that make Liv Hospital a trusted destination for patients from around the world seeking high‑quality hematology care.
Von Willebrand disease encompasses a spectrum of bleeding disorders caused by quantitative or qualitative defects in von Willebrand factor (VWF), a protein essential for platelet adhesion and clot stabilization. The disease is classified into three primary types:
Setting clear treatment and management objectives is crucial for each patient:
By aligning therapeutic choices with these goals, clinicians can deliver precise treatment and management that reduces bleeding episodes while minimizing unnecessary exposure to blood products.
Medication remains the cornerstone of VWD treatment and management. The choice of agent depends on disease type, severity, and the clinical situation (e.g., prophylaxis versus on‑demand treatment).
Desmopressin stimulates the release of endogenous VWF from endothelial cells, making it ideal for patients with Type 1 and certain Type 2 subtypes who demonstrate a positive DDAVP trial. Typical dosing is 0.3 µg/kg administered intravenously or intranasally, with a repeat dose possible after 24 hours.
For patients who do not respond to DDAVP or who have severe deficiency (Type 2 and Type 3), plasma‑derived or recombinant VWF/FVIII concentrates are used. These products provide both VWF and factor VIII, ensuring robust clot formation. Dosing is individualized, often calculated based on body weight and desired rise in VWF activity.
Tranexamic acid and epsilon‑aminocaproic acid inhibit fibrinolysis and are valuable adjuncts for mucosal bleeding, dental procedures, or as prophylaxis during menstruation. They are typically administered orally or intravenously, depending on the severity of the bleed.
These pharmacologic options form the backbone of effective treatment and management plans, allowing clinicians to tailor therapy to each patient’s unique profile.
While medication addresses the physiological deficit, non‑pharmacologic measures help patients navigate daily life safely. Incorporating these strategies into the overall treatment and management plan can substantially reduce bleeding risk.
Prior to any dental work, patients should schedule a pre‑procedure evaluation at Liv Hospital. A tailored prophylactic regimen (e.g., DDAVP or VWF concentrate) can be administered 30–60 minutes before the procedure to ensure optimal hemostasis.
Women with VWD often experience heavy menstrual bleeding. Options include tranexamic acid during menses, hormonal contraceptives to regulate flow, and, when necessary, short‑term VWF replacement therapy.
These practical measures complement the overall treatment and management plan, empowering patients to lead active, fulfilling lives.
When surgical or invasive procedures are unavoidable, meticulous planning is essential for successful treatment and management. The multidisciplinary team at Liv Hospital coordinates hematology, anesthesia, and surgery to minimize peri‑operative bleeding.
Administer VWF concentrate 30 minutes before incision, aiming for a VWF:RCo activity of 80–100 % for major surgery. For minor procedures, a target of 50 % may suffice. Continuous monitoring of coagulation parameters guides additional dosing.
Maintain therapeutic VWF levels for 24–72 hours post‑procedure, depending on the surgical site and healing progress. Antifibrinolytics are often added to protect against delayed bleeding.
By integrating precise factor replacement with vigilant monitoring, surgical treatment and management can be performed safely, reducing complications and shortening recovery time.
Long‑term treatment and management of VWD hinges on regular monitoring and the ability to adapt therapy as the patient’s needs evolve. Liv Hospital employs a structured follow‑up protocol to ensure optimal outcomes.
Each patient receives a personalized care plan that outlines:
Liv Hospital’s international patient services include tele‑medicine consultations, secure electronic health records, and a dedicated patient portal where individuals can upload bleeding logs, laboratory results, and communicate directly with their hematology team.
Continuous assessment enables clinicians to modify the therapeutic regimen promptly, ensuring that ongoing treatment and management remains both effective and patient‑centric.
For patients traveling from abroad, Liv Hospital offers a comprehensive suite of services designed to streamline the entire treatment and management journey.
These integrated services remove logistical barriers, allowing international patients to focus solely on their health while receiving world‑class hematology care.
Research in VWD is rapidly advancing, promising new options that could reshape the landscape of treatment and management. Key developments include:
Liv Hospital participates in international clinical trials, providing eligible patients access to cutting‑edge treatments under expert supervision. Staying informed about these innovations ensures that patients can benefit from the most advanced treatment and management strategies as they become available.
Liv Hospital combines JCI accreditation, a multidisciplinary team of hematology specialists, and a dedicated international patient program to deliver safe, effective care for Von Willebrand disease. Our state‑of‑the‑art facilities, evidence‑based protocols, and personalized support services ensure that patients receive seamless, high‑quality treatment from diagnosis through long‑term follow‑up.
Ready to take control of your health? Contact Liv Hospital today to schedule a comprehensive evaluation and begin your personalized treatment and management plan. Our international patient team is here to guide you every step of the way.
Send us all your questions or requests, and our expert team will assist you.
Von Willebrand disease (VWD) is divided into three primary categories based on the amount and functionality of von Willebrand factor (VWF). Type 1 is the most common and involves a mild‑to‑moderate reduction in VWF levels. Type 2 includes several sub‑types where the VWF protein is present but dysfunctional; each subtype (2A, 2B, 2M, 2N) affects platelet binding or factor VIII interaction differently. Type 3 is the rarest and most severe form, characterized by almost no VWF and often accompanied by a severe factor VIII deficiency, leading to a bleeding phenotype similar to hemophilia A. Correct classification guides therapy selection, such as DDAVP for many Type 1 patients and VWF/FVIII concentrates for Type 2 and Type 3.
Desmopressin (DDAVP) works by stimulating endothelial cells to release stored VWF, making it an effective first‑line therapy for patients with mild quantitative deficiency (Type 1) and certain qualitative defects (e.g., Type 2A, 2M) that respond to a test dose. The typical regimen is 0.3 µg/kg given intravenously or intranasally, with a repeat dose possible after 24 hours. Patients must be monitored for hyponatremia and fluid overload, especially in children or those with renal impairment. A DDAVP trial—measuring VWF activity before and after administration—confirms responsiveness before routine use.
For any invasive or surgical intervention, a multidisciplinary team evaluates VWF antigen, activity (ristocetin cofactor), and factor VIII levels. A DDAVP trial may be performed if appropriate. Based on expected blood loss, clinicians set target VWF:RCo activity: 50‑70% for minor procedures (e.g., dental extraction), 70‑100% for moderate surgeries, and 100‑150% for major operations. VWF/FVIII concentrate is administered 30 minutes before incision, with repeat dosing guided by real‑time coagulation tests. Post‑operative care maintains therapeutic VWF levels for 24‑72 hours and often adds tranexamic acid to prevent delayed bleeding.
Beyond medication, patients can adopt several practical steps to minimize bleeding episodes. Gentle oral hygiene with a soft toothbrush and avoiding aggressive flossing reduces gum bleeding. During contact sports, wearing helmets, shin guards, and mouthguards protects against trauma. A diet rich in iron, vitamin C, and lean protein supports hematopoiesis and vascular health, helping prevent anemia from chronic blood loss. Regular dental visits allow early detection of oral lesions. Women with VWD benefit from tranexamic acid during menses, hormonal contraceptives to regulate flow, and short‑term VWF replacement if bleeding is severe.
International patients receive comprehensive support from Liv Hospital’s International Patient Services. The hospital provides tele‑medicine consultations before travel, allowing clinicians to review medical history and plan treatment. A secure electronic health record portal lets patients upload bleeding logs, lab results, and communicate directly with their hematology team. Language assistance, visa guidance, and airport transfers are arranged to reduce logistical stress. In‑hospital, a multidisciplinary team—including hematologists, anesthesiologists, and surgeons—coordinates pre‑operative assessments, factor replacement, and post‑operative follow‑up, ensuring continuity of care from the patient’s home country to Turkey.
Long‑term management relies on scheduled laboratory monitoring to track VWF antigen levels, VWF activity (ristocetin cofactor), and factor VIII activity. Clinicians also use standardized bleeding assessment tools, such as the ISTH Bleeding Score, to quantify clinical severity over time. For patients on prophylactic VWF concentrate, pharmacokinetic profiling helps determine optimal dosing intervals and amounts, reducing both under‑ and over‑treatment. Follow‑up visits are typically every 6‑12 months, during which therapy is reassessed, emergency protocols are reviewed, and any new comorbidities are addressed. The patient portal facilitates real‑time data sharing, enabling rapid adjustments to the care plan.
BlogHematologyFeb 19, 2026Blood donation is a key act that saves many lives. But, some medical conditions, like hemophilia, make it r...
BlogHematologyOct 06, 2025Rare bleeding disorders affect millions worldwide, leaving patients and healthcare providers searching for ...
BlogHematologyFeb 19, 2026We are looking into how desmopressin changes medicine. It’s a synthetic hormone that has made a big d...
BlogHematologyFeb 19, 2026Uncontrolled bleeding is a big risk, mainly for those on anticoagulants. We’ll look at medicines to s...
BlogHematologyFeb 19, 2026Diagnosing some blood disorders is tough. Conditions like Von Willebrand disease and myelodysplastic syndro...
BlogHematologyOct 21, 2025Inherited bleeding disorders affect thousands worldwide. Hemophilia and von Willebrand disease are the most...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
